Tomorrow's Science For Today's Clinician
The Drug Controller General of India cleared the oral drug for emergency use on December 28, and several Indian generic pharma companies have already launched the drug in the country under the licence issued by Merck. However, the Indian Council of Medical Research (ICMR) later expressed serious concerns over the safety profile of the drug.
The study reviewed how the virus replicates in human cells and persists in the human body. Scientists have been working on the causes of ‘long Covid’ for a long time after the prevalence of the persisting disease, even after the patients tested negative after infection.
According to an analysis by scientists at the FDA, this experimental drug reduced the risk of hospitalization or death from COVID-19 only by about 30 percent compared to a placebo.
Prof. Field’s team analysed UKLS participants in the intervention group and in the usual-care group and followed them for 7.4 years. It has to be noted that the relative benefit in terms of lung cancer mortality was seen most strongly in the three to six years after randomization.
Technology is all around us. Some of it is even starting to look a bit unreal. Eric Topol, in his book “The Patient Will See You Now – The Future of Medicine Is in Your Hands”,
Arvind Krishnamurthy, Vijayalakshmi Ramshankar, Kanchan Murhekar, Vidyarani Shyamsundar, Pavithra B Desai, Purvish Parikh
(Department of Surgical Oncology, Cancer Institute (WIA), Adyar, Chennai, India, Department Preventive Oncology Research, Cancer Institute (WIA), Adyar, Chennai, India, Department of Pathology, Cancer Institute (WIA), Adyar,